Scarica l'app Stockscreener
3.85
2.28%
-0.09
Pre-mercato:
3.87
0.02
+0.52%
Precedente Chiudi:
$3.94
Aprire:
$3.91
Volume 24 ore:
909.97K
Relative Volume:
0.84
Capitalizzazione di mercato:
$271.77M
Reddito:
$20.76M
Utile/perdita netta:
$-132.49M
Rapporto P/E:
-1.4419
EPS:
-2.67
Flusso di cassa netto:
$-108.55M
1 W Prestazione:
+2.94%
1M Prestazione:
-2.53%
6M Prestazione:
-36.15%
1 anno Prestazione:
-34.86%
Intervallo 1D:
$3.79
$4.025
Intervallo di 1 settimana:
$3.79
$4.07
Portata 52W:
$3.38
$11.88
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Nome
C 4 Therapeutics Inc
Settore
Industria
Telefono
(617) 231-0700
Indirizzo
490 ARSENAL WAY, WATERTOWN
Confronta CCCC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
3.85 | 271.77M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Iniziato | Stephens | Equal-Weight |
| 2024-01-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-12-13 | Aggiornamento | Stifel | Hold → Buy |
| 2023-02-24 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Underweight |
| 2022-04-28 | Iniziato | Credit Suisse | Underperform |
| 2022-04-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-10 | Iniziato | JP Morgan | Overweight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-11-23 | Iniziato | BofA Securities | Buy |
| 2021-10-14 | Iniziato | SVB Leerink | Mkt Perform |
| 2021-09-30 | Iniziato | Stifel | Hold |
| 2021-06-04 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-10-27 | Iniziato | BMO Capital Markets | Outperform |
| 2020-10-27 | Iniziato | Jefferies | Buy |
Mostra tutto
C 4 Therapeutics Inc Borsa (CCCC) Ultime notizie
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics stock rises on portfolio update (CCCC:NASDAQ) - Seeking Alpha
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology - The Manila Times
C4 Therapeutics progresses with key 2025 clinical trials - Investing.com
C4 Therapeutics Reveals Strong Cancer Drug Pipeline Progress, Sets Key 2025 Milestones - StockTitan
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives $10.67 Consensus PT from Brokerages - MarketBeat
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
C4 Therapeutics stock plunges to 52-week low of $3.43 - Investing.com India
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
NUT Midline Carcinoma Treatment Market Research Report 2023-2024 & 2034: Market Forecast by Treatment, Route of Administration, and End-User Across 5 Regions and 17+ Countries - GlobeNewswire Inc.
Equities Analysts Issue Forecasts for C4 Therapeutics FY2029 Earnings - MarketBeat
C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
C4 Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Here's Why C4 Therapeutics (CCCC) Is a Great 'Buy the Bottom' Stock Now - MSN
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Up 11.0% in December - MarketBeat
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Why C4 Therapeutics (CCCC) Is One of the Best Biotech Penny Stocks to Invest in Now? - Yahoo Finance
C4 Therapeutics stock hits 52-week low at $3.6 amid market challenges - Investing.com
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
State Street Corp Sells 188,035 Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) - MarketBeat
Brokerages Set C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target at $10.67 - MarketBeat
Wells Fargo Upgrades C4 Therapeutics (CCCC) - MSN
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics (NASDAQ:CCCC) Upgraded at Wells Fargo & Company - MarketBeat
C4 Therapeutics stock hits 52-week low at $3.77 - Investing.com
Fmr LLC Buys 162,314 Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) - MarketBeat
C 4 Therapeutics Inc Azioni (CCCC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):